PDE III Inhibitors
2 drugsAbout PDE III
Phosphodiesterase III (PDE III) regulates intracellular levels of cAMP and cGMP by breaking them down. This enzyme influences physiological processes, particularly in cardiovascular and respiratory systems, impacting smooth muscle relaxation and cardiac contractility.
While there is currently no genetic evidence directly linking PDE III to specific diseases, its role in critical pathways makes it a relevant target. Therapeutic interventions modulating PDE III activity have shown promise, especially in respiratory conditions.
PDE III is targeted by one FDA-approved drug, THEO-24, a small molecule approved in 1983 for respiratory indications. ENDO OPERATIONS is the sole company with an approved PDE III-targeting drug.
Top PDE III Drugs
ENDO OPERATIONS is the only company with an approved drug targeting PDE III.
The lack of competition suggests high barriers to entry or limited market potential.
PDE III Drug Modality Landscape
Modalities
Routes of Administration
PDE III is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could create differentiation.
PDE III Clinical Trials 50 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PDE III. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 9 | 6 | 2 | 1 | 75% |
| Phase 2 | 20 | 14 | 0 | 6 | 100% |
| Phase 3 | 8 | 7 | 0 | 1 | 100% |
| Phase 4 | 13 | 11 | 1 | 1 | 92% |
Top Sponsors
By Modality
Top Conditions
PDE III Drug Approval Timeline (1983 - 2024)
THEO-24 was the first and only drug approved in 1983, representing the entire approval history.
The absence of recent approvals indicates a saturated market or challenges in developing new PDE III modulators.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 36 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PDE III. A trial counts if an approved drug acting on PDE III is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.